Immunogenicity and efficacy of Schmallenberg virus envelope glycoprotein subunit vaccines
- Author:
Abaineh D ENDALEW
1
;
Bonto FABURAY
;
Jessie D TRUJILLO
;
Natasha N GAUDREAULT
;
A Sally DAVIS
;
Vinay SHIVANNA
;
Sun Young SUNWOO
;
Wenjun MA
;
Barbara S DROLET
;
D Scott MCVEY
;
Igor MOROZOV
;
William C WILSON
;
Juergen A RICHT
Author Information
- Publication Type:Original Article
- Keywords: Schmallenberg virus; subunit vaccine; cattle
- MeSH: Animals; Antibodies; Antibodies, Neutralizing; Baculoviridae; Cattle; Congenital Abnormalities; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Orthobunyavirus; RNA; Sheep; Stillbirth; Vaccination; Vaccines; Vaccines, Attenuated; Vaccines, Subunit; Viremia
- From:Journal of Veterinary Science 2019;20(6):e58-
- CountryRepublic of Korea
- Language:English
- Abstract: The Schmallenberg virus (SBV) is an orthobunyavirus that causes abortions, stillbirths, and congenital defects in pregnant sheep and cattle. Inactivated or live attenuated vaccines have been developed in endemic countries, but there is still interest in the development of SBV vaccines that would allow Differentiating Infected from Vaccinated Animals (DIVA). Therefore, an attempt was made to develop novel DIVA-compatible SBV vaccines using SBV glycoproteins expressed in baculovirus. All vaccines and phosphate buffered saline (PBS) controls were prepared with adjuvant and administered subcutaneously to cattle at 6 month of age. The first trial included 2 groups of animals vaccinated with either carboxyl-terminus glycoprotein (Gc) or PBS and boosted after 2 weeks. In the second trial, 3 groups of cattle were administered either Gc, Gc and amino-terminus glycoprotein (Gn), or PBS with a booster vaccination after 3 weeks. The animals were challenged with SBV 9 days after the booster vaccination in the first study, and 3 weeks after the booster vaccination in the second study. Using a SBV Gc-specific enzyme-linked immunosorbent assay, antibodies were first detected in serum samples 14 days after the first vaccination in both trials, and peaked on days 7 and 9 after the booster in the first and second trials, respectively. Low titers of neutralizing antibodies were detected in serum from only 3/6 and 2/4 animals in the first and second trial, respectively, at 14 days after the first vaccination. The titers increased 2 to 3-fold after the booster vaccination. SBV-specific RNA was detected in the serum and selective tissues in all animals after SBV challenge independent of vaccination status. The SBV candidate vaccines neither prevented viremia nor conferred protection against SBV infection.
